Dr. James Karlowsky

Dr. James A. Karlowsky

Professor, Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba

Provincial Medical Director, Clinical Microbiology, Diagnostic Services, Shared Health Manitoba

Degrees: B.Sc.[Pharmacy] (Manitoba, 1991), Ph.D. [Medical Microbiology] (Manitoba, 1996)

Postdoctoral Fellowships: Pharmacy (Manitoba, 1998), Medical Microbiology (Iowa, 2005)

Professional Certifications/Awarded Fellowships: D[ABMM] (2005), F[CCM] (2005), F[IDSA] (2007), F[AAM] (2015)

Office address: Department of Clinical Microbiology, Saint Boniface Hospital, 409 Taché Avenue, L4025-10, Winnipeg, Manitoba, R2H 2A6, Canada

Office telephone: (204) 237 2105; E-mail: jkarlowsky@sharedhealthmb.ca

Research Interests:

Antimicrobial resistance, clinical microbiology methods

Recent Publications:

1. Karlowsky JA, Lagacé-Wiens PRS, Laing NM, Baxter MR, Adam HJ, Zhanel GG. Susceptibility of clinical isolates of Escherichia coli to fosfomycin as measured by four in vitro testing methods. Journal of Clinical Microbiology, 2020;58(10):e01306-20.
2. Karlowsky JA, Hackel MA, Bouchillon SK, Sahm DF. In vitro activity of WCK 5222 (cefepime-zidebactam) against worldwide collected Gram-negative bacilli not susceptible to carbapenems. Antimicrobial Agents and Chemotherapy, 2020;64(12):e01432-20.
3. Karlowsky JA, Lob SH, Raddatz J, DePestel D, Young K, Motyl M, Sahm DF. Activity of imipenem-relebactam and ceftolozane-tazobactam against Gram-negative isolates with difficult-to-treat resistance – SMART United States 2015-2017. Clinical Infectious Diseases, 2020; doi:10.1093/cid/ciaa381.
4. Karlowsky JA, Adam HJ, Dutka C, Baxter MR, Nichol KA, Laing NM, Golding GR, Zhanel GG. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrheal stools of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017. Journal of Antimicrobial Chemotherapy, 2020;75(7):1824-1832.
5. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART surveillance United States 2015-2017. International Journal of Antimicrobial Agents, 2020;55(1):105841.